Welcome to the New Nuclear Medicine Technologist Section, providing you access to everything you need on the SNMMI website in one place.
Access to 100 of the premier sessions from the SNMMI 2016 Annual Meeting! Learn more.
SNMMI educational programs are designed to meet the professional development needs of technologists in the field of nuclear medicine and molecular imaging, as well as providing them with continuing education credit opportunities. SNMMI is an ARRT-recognized conitinuing education mechanism (RCEEMs) provider through the Society's Verification Of Involvement in Continuing Education (VOICE) program.
Introducing a new member-benefit. Stay on top of the latest trends and advancements in the profession with quarterly technologist-focused webinars—free for SNMMI-TS members.
Upcoming webinar: Join Nanci A Burchell and Missy Stump on Thursday, May 19 at 3:00 pm ET for a complimentary webinar: "Current Practices in Pediatric Nuclear Medicine."
The PET Online Review Workshop is designed to help prepare technologists for the NMTCB's PET Exam. Following the NMTCB's content outline, the workshop offers a comprehensive review of both PET and PET/CT.
The NCT (Nuclear Cardiology Technologist) Online Review Workshop is designed to prepare technologists for the NMTCB's NCT Exam. The course reviews the NMTCB's nuclear cardiology examination content specifications.
The academy will be a two-day course with an assemblage of current SNMMI-TS Leadership, key members of the SNMMI-TS, and SNMMI Staff who have dedicated themselves to improving SNMMI-TS achievement in the Nuclear Medicine and related fields. Lectures will be complimented with team building exercises which will enhance networking opportunities. Each lecture will consider a different aspect of leadership and will be led by technologists or keynote speakers with an intimate knowledge of the subject. The overall goal is to assemble a group of SNMMI-TS Leaders who understand the crucial role of leadership development and who are eager to begin the path to SNMMI-TS Leadership and organizational success.
The spectrum of responsibilities for a nuclear medicine technologist varies widely across the United States. Practice components presented in this document provide a basis for establishing the areas of knowledge and performance for the nuclear medicine technologist. The nuclear medicine technologist must be in compliance with all federal, state, and institutional guidelines, including proper documentation of initial and continued competency in those practices and activities.
Continuing education is a necessary component in maintaining the skills required to perform all duties and tasks of the nuclear medicine technologist in this ever-evolving field.
The Nuclear Medicine Technologist Scope of Practice and Performance Standards document is intended to set forth the standards in important areas of the nuclear medicine technologist’s responsibilities. It may not cover all areas which may present themselves in actual practice. These standards do not supersede the judgment of the individual nuclear medicine technologist and other healthcare professionals serving the patient in light of all of the facts of the individual case. THE SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING AND THE SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING TECHNOLOGIST SECTION DISCLAIM ALL LIABILITY ARISING FROM USE OF THESE DOCUMENTS.
NMT Scope of Practice and Performance Standards - Approved September 2016
Visit SNMMI's Career Center.
The nuclear medicine and molecular imaging technologists are highly specialized healthcare professionals who works closely with the nuclear medicine physician. Some of the technologist’s primary responsibilities are to: Prepare and administer radioactive chemical compounds, known as radiopharmaceuticals and to administer adjunctive medications in order to perform patient imaging procedures using sophisticated instrumentation; Process data and enhance digital images using advanced computer technology; Provide images, data analysis, and patient information to the physician for diagnostic interpretation; and Evaluate new procedures for appropriateness in specific clinical settings and patient populations.
The Society of Nuclear Medicine and Molecular Imaging Technologist Section as part of the SNMMI, is constantly striving to make a difference in the way nuclear medicine and molecular imaging technologists receive academic and continuing education as well as information concerning new procedures, technologies and equipment. Research has been a vital part of SNMMI-TS activities for many years, as has monitoring federal regulation and influencing decisions that affect the practice of nuclear medicine.
In addition to providing discussion forums and publishing journals, newsletters and books, SNMMI-TS also sponsors international meetings and workshops designed to increase the competencies of nuclear medicine practitioners and to promote new scientific advances. The activities of the SNMMI-TS National Council of Representatives, volunteer committee members, and staff focus on improving the quality of care for the patients served by technologists around the world.
In nuclear medicine, the goal is to keep radiation exposure at a minimum, while obtaining quality images. Optimal dosing for individual patients can be difficult to determine. That’s where 3D-printed organ models of varying size and shape could be of great use. In a study reported in the December issue of "The Journal of Nuclear Medicine," researchers at the University of Würzburg in Germany focused on kidneys to demonstrate that low-cost 3D printing techniques can be used for quantitative SPECT/CT imaging.
New research demonstrates that a novel imaging agent can quickly and accurately detect metastasis of prostate cancer, even in areas where detection has previously been difficult. Published in the December issue of "The Journal of Nuclear Medicine," the Phase 1 dose-escalation study of Zr-89-desferrioxamine-IAB2M (Zr-89-Df-IAB2M), an anti-PSMA minibody, in patients with metastatic prostate cancer shows its effectiveness in targeting both bone and soft tissue lesions.
Researchers at Memorial Sloan Kettering Cancer Center demonstrated that a new PET imaging agent can detect metastatic prostate cancer in regions that it has previously been difficult to spot. Results from the Phase 1 dose-escalation study of Zr-89-deferrioxamine-IAB2M were published in the December issue of "The Journal of Nuclear Medicine."
(MI: Making a Difference)
On Wednesday, November 30, the House passed the 21st Century Cures legislation 392-26, sending the sweeping FDA and CMS reform package to the Senate.
(Government Relations News)
October 19, 2016 | 3:00pm ET
Speaker: Maria Costello
This presentation will discuss the goals and benefits of accreditation, the value of accreditation from a facility perspective, and an overview of the IAC accreditation program. Common pitfalls experienced by facilities seeking IAC accreditation will also be reviewed.
1.0 VOICE Credit Available.